<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05795088</url>
  </required_header>
  <id_info>
    <org_study_id>3884</org_study_id>
    <nct_id>NCT05795088</nct_id>
  </id_info>
  <brief_title>Continuous Theta Burst Stimulation as Potential Biomarker of Levodopa-induced Dyskinesias in Parkinson's Disease</brief_title>
  <official_title>Role of Continuous Theta Burst Stimulation as Potential Biomarker of Levodopa-induced Dyskinesias in Patients With Parkinson's Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary endpoint of the study is to identify a neurophysiological biomarker (absence of&#xD;
      synaptic depotentiation at primary motor cortex , measured as change in the amplitude of&#xD;
      motor evoked potentials recorded at the dorsal first interosseus muscle after administration&#xD;
      of neurophysiological cTBS depotentiation protocol) as predictor of the development of&#xD;
      Levodopa-induced dyskinesia in patients with Parkinson's disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 16, 2022</start_date>
  <completion_date type="Anticipated">February 28, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alterations of synaptic depotentiation in primary motor cortex</measure>
    <time_frame>3 years</time_frame>
    <description>Alterations of synaptic depotentiation in primary motor cortex will be measured as change in the amplitude of motor evoked potentials recorded at the dorsal first interosseus muscle after administration of depotentiation protocol of continuous theta burst stimulation. Alterations of synaptic depotentiation at the baseline evaluation will be compared between patients who will develop and patients who will not develop dyskinesias (assessed by Unified Dyskinesia Rating Scale part III, range 0-112) during the follow-up.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Patients with parkinson's disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous theta burst stimulation</intervention_name>
    <description>Two sessions of continuous theta burst stimulation over primary motor cortex to explore synaptic plasticity in Patients with Parkinson's disease</description>
    <arm_group_label>Patients with parkinson's disease</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with diagnosis of idiopathic Parkinson's disease according to Movement&#xD;
             Disorder Society (MDS) criteria;&#xD;
&#xD;
          -  age between 30 and 80 years;&#xD;
&#xD;
          -  ongoing therapy with levodopa;&#xD;
&#xD;
          -  fulfillment of requirements for the application of transcranial magnetic stimulation&#xD;
             (TMS), assessed by completion of the TMS screening questionnaire.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients unable to give informed consent;&#xD;
&#xD;
          -  cognitive impairment (MMSE â‰¤ 24);&#xD;
&#xD;
          -  history of epilepsy;&#xD;
&#xD;
          -  pregnant women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paolo Calabresi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francesco Bove, MD</last_name>
    <phone>+390630156433</phone>
    <email>francesco.bove@policlinicogemelli.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Flavia Torlizzi</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Flavia Torlizzi</last_name>
      <phone>+390630156433</phone>
      <email>flavia.torlizzi@policlinicogemelli.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2023</verification_date>
  <study_first_submitted>February 21, 2023</study_first_submitted>
  <study_first_submitted_qc>March 20, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2023</study_first_posted>
  <last_update_submitted>March 20, 2023</last_update_submitted>
  <last_update_submitted_qc>March 20, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dyskinesias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

